Aortic stenosis 

V.I. Pavliuk , O.J. Zharinov , N.V. Ponich

References 

1. Павлюк В.І. Практична ехокардіографія / За ред.О.Й. Жарінова.– Львів: Медицина світу, 2014.– 156 с.
2. Armstrong W.F., Ryan T., Feigenbaum H. Feigenbaum’s Echo-cardiography.– Lippincott Williams & Wilkins, 2010.– 785 p.
3. Baumgartner H., Hung J. et al. Echocardiographic assess-ment of valve stenosis: EAE/ASE recommendations forclinical practice // J. Am. Soc. Echocardiogr.– 2009.– Vol. 22.–P. 1–23.
4. Bellamy M.F., Pellikka P.A., Klarich K.W. et al. Association ofcholesterol levels, hydroxymethylglutaryl coenzyme-Areductase inhibitor treatment, and progression of aorticstenosis in the community // J. Am. Coll. Cardiol.– 2002.–Vol. 40.– P. 1723–1730.
5. Bonow R.O., Carabello B.A., Chatterjee K. et al. 2008 focusedupdate incorporated into the ACC/AHA 2006 guidelines forthe management of patients with valvular heart disease: areport of the American College of Cardiology/AmericanHeart Association Task Force on Management of PatientsWith Valvular Heart Disease // J. Am. Coll. Cardiol.– 2008.–Vol. 52.– Р. e1–e142.
6. Brown J.M., O’Brien S.M., Wu C. et al. Isolated aortic valvereplacement in North America comprising 108,687 patientsin 10 years: changes in risks, valve types, and outcomes in theSociety of Thoracic Surgeons National Database // J. Thorac.Cardiovasc. Surg.– 2009.– Vol. 137.– P. 82–90.7. Chan K.L., Teo K., Dumesnil J.G. et al. Effect of Lipid loweringwith rosuvastatin on progression of aortic stenosis: results ofthe aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial // Circulation.–2010.– Vol. 121.– P. 306–314.
8. Cowell S.J., Newby D.E., Prescott R.J. et al. A randomized trialof intensive lipid-lowering therapy in calcific aortic stenosis //New Engl. J. Med.– 2005.– Vol. 352.– P. 2389–2397.
9. Freeman R.V., Otto C.M. Spectrum of calcific aortic valvedisease: pathogenesis, disease progression, and treatmentstrategies // Circulation.– 2005.– Vol. 111.– P. 3316–3326.
10. Grube E., Schuler G., Buellesfeld L. et al. Percutaneous aorticvalve replacement for severe aortic stenosis in high-riskpatients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-dayclinical outcome // J. Am. Coll. Cardiol.– 2007.– Vol. 50.–P. 69–76.
11. Iung B., Baron G., Butchart EG. et al. A prospective survey ofpatients with valvular heart disease in Europe: the EuroHeart Survey on valvular heart disease // Eur. Heart J.– 2003.–Vol. 24.– P. 1231–1243.
12. Lombard J.T., Selzer A. Valvular aortic stenosis. A clinical andhemodynamic profile of patients // Ann. Intern. Med.–1987.– Vol. 106.– P. 292–298.
13. Moura L.M., Ramos S.F., Zamorano J.L. et al. Rosuvastatinaffecting aortic valve endothelium to slow the progressionof aortic stenosis // J. Am. Coll. Cardiol.– 2007.– Vol. 49.P. 554–561.14. Novaro G.M., Tiong I.Y., Pearce G.L. et al. Effect ofhydroxymethylglutaryl coenzyme a reductase inhibitors onthe progression of calcific aortic stenosis // Circulation.–2001.– Vol. 104.– P. 2205–2209.
15. O’Brien K.D. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more) // Arterioscler. Thromb. Vasc. Biol.– 2006.– Vol. 26.– P. 1721–1728.
16. Otto C.M. Calcific aortic stenosis – time to look more closelyat the valve // New Engl. J. Med.– 2008.– Vol. 359.– P. 1395–1398.
17. Otto C.M., Lind B.K., Kitzman D.W. et al. Association ofaortic-valve sclerosis with cardiovascular mortality andmorbidity in the elderly // New Engl. J. Med.– 1999.– Vol.341.– P. 142–147.
18. Otto C.M., Mickel M.C., Kennedy J.W. et al. Three-yearoutcome after balloon aortic valvuloplasty. Insights intoprognosis of valvular aortic stenosis // Circulation.– 1994.–Vol. 89.– P. 642–650.
19. Ozumi K., Tasaki H., Yamashita K. et al. Valvular and supra-valvular aortic stenosis in heterozygous familial hyper-cholesterolemia, a case report // J. Atheroscler. Thromb.–2005.– Vol. 12.– P. 289–293
20. Piazza N., Grube E., Gerckens U. et al. Procedural and 30-dayoutcomes following transcatheter aortic valve implantationusing the third generation (18 Fr) corevalve revalving system:results from the multicentre, expanded evaluation registry1-year following CE mark approval // EuroIntervention.–2008.– Vol. 4.– P. 242–249.
21. Ross J. Jr., Braunwald E. Aortic stenosis // Circulation.– 1968.–Vol. 38 (Suppl. 1).– P. 1–7.
22. Rosenhek R., Binder T., Porenta G. et al. Predictors of out-come in severe, asymptomatic aortic stenosis // New Engl. J.Med.– 2000.– Vol. 343.– P. 611–617.
23. Rossebo A.B., Pedersen T.R., Boman K. et al. Intensive lipidlowering with simvastatin and ezetimibe in aortic stenosis //New Engl. J. Med.– 2008.– Vol. 359.– P. 1343–1356.
24. Sharma U.C., Barenbrug P., Pokharel S. et al. Systematicreview of the outcome of aortic valve replacement in pa-tients with aortic stenosis // Ann. Thorac. Surg.– 2004.–Vol. 78.– P. 90–95.
25. Schwarz F., Baumann P., Manthey J. et al. The effect of aorticvalve replacement on survival // Circulation.– 1982.– Vol. 66.–P. 1105–1110.
26. Stewart B.F., Siscovick D., Lind B.K. et al. Clinical factorsassociated with calcific aortic valve disease. CardiovascularHealth Study // J. Am. Coll. Cardiol.– 1997.– Vol. 29.– P. 630–634.
27. Stoddard M.F., Hammons R.T., Longaker R.A. Dopplertransesophageal echocardiographic determination of aorticvalve area in adults with aortic stenosis // Amer. HeartJ.– 1996.– Vol. 132.– P. 337–342.
28. Rahimtoola S.H. Catheter balloon valvuloplasty for severecalcific aortic stenosis: a limited role // J. Am. Coll. Cardiol.–1994.– Vol. 23.– P. 1076–1078.
29. Vaquette B., Corbineau H., Laurent M. et al. Valve replace-ment in patients with critical aortic stenosis and depressedleft ventricular function: predictors of operative risk, leftventricular function recovery, and long-term outcome //Heart.– 2005.– Vol. 91.– P. 1324–1329.
30. Webb J.G., Altwegg L., Masson J.B. et al. A new transcatheteraortic valve and percutaneous valve delivery system //J. Amer. Coll. Cardiol.– 2009.– Vol. 53.– P. 1855–1858.

Electrophysiological features of cardiac rhythm changes in patients with decreased myocardial contractility after cord blood stem cell transplantation during short-term follow-up 

O.Yu. Usenko, A.V. Yakushev, O.V. Lisun, T.M. Domanskiy, V.F. Onishchenko

References

1. Макаров Л.М. Особенности использования вариа бельности ритма серца у больных с болезнями сердца //Физиология человека.– 2002.– Т. 28, № 3.– С. 65–68.
2. Bartunek J., Vanderheyden M., Vandekerckhove B. et al.Intracoronary injection of CD133-positive enriched bonemarrow progenitor cells promotes cardiac recovery afterrecent myocardial infarction: feasibility and safety //Circulation.– 2005.– Vol. 112, Suppl. I.– P. I–178–II–83.3. Britten M. B., Abolmaali N.D., Assmus B. et al. Infarct remodelingafter intracoronary progenitor cell treatment inpatients with acute myocardial infarction (TOPCARE–AMI):mechanistic insights from serial contrast-enhanced magneticresonance imaging // Circulation.– 2003.– Vol. 108.– P. 2212–2218.
4. Chang M.G., Tung L., Sekar R.B. et al. Proarrhythmic potentialof mesenchymal stem cell transplantation revealed in anin vitro coculture model // Circulation.– 2006.– Vol. 113.–P. 1832–1841.
5. Dabrowski A., Dabrowski B., Piotrowicz R. Суточноемониторирование ЭКГ.– М.: Медпрактика, 2000.–С. 76–85.
6. Gutstein D.E., Morley G.E., Tamaddon H. et al. Conductionslowing and sudden arrhythmic death in mice with cardiac–restricted inactivation of connexin43 // Circ. Res.– 2001.–Vol. 88.– P. 333–339.
7. Kolettis T.M. Arrhythmogenesis after cell transplantationpost-myocardial infarction: four burning questions and someanswers // Cardiovasc. Res.– 2006.– Vol. 69.– P. 299–301.
8. Makkar R.R., Lill M., Chen P.S. Stem cell therapy for myocardialrepair: is it arrhythmogenic? // J. Am. Coll. Cardiol.–2003 – Vol. 42.– P. 2070–2072.
9. Rubart M., Soonpaa M.H., Nakajima H., Field L.J.Spontaneous and evoked intracellular calcium transientsin donor–derived myocytes following intracardiac myoblasttransplantation // J. Clin. Invest.– 2004.– Vol. 114.–P. 775–783.

Case of recurrence of left atrial myxoma with observance principles of adequacy operation

R.M. Vitovsky, V.P. Zaharova, V.V. Isaenko, О.A. Pishchurin, A.V. Krivenky, I.G. Yakovenko, E.O. Bilynsky, A.Z. Paratsiy, T.I. Dedkova, E.V. Satmari, L.S. Chernyakova

References

1. Барбухатти К.О., Антонов Г.Н., Фаримов В.А., Терман Е.А.Восьмилетний опыт хирургического лечения миксом сердца // Грудная и сердечно-сосудистая хирургия.– 2011.–№ 3.– С. 23–27.
2. Bireta C., Popov A. F., Schotola H. et al. Carney-Complex:multiple resections of recurrent cardiac myxoma // J.Cardiothorac. Surg. – 2011.– Vol. 6.– P. 12.
3. Borkar S.S., Kamath S.G., Kashyap N. et al. Carney Complex:case report and review // J. Cardiothorac. Surg.– 2011.–Vol. 6.– P. 25.
4. Guenther F., Siepe M., Schlensak C. et al. Images in cardiovas-cular medicine. Recurrence of a familial giant multilocularcardiac myxoma in a patient with Carney’s complex // Circulation.– 2011.– Vol. 123, N 8.– P. 929–932.
5. Hill M., Cherry C., Maloney M., Midyette P. Surgical resection of atrial myxomas // AORN J.– 2010.– Vol. 92, N 4.– P. 393–406.
6. Oliveira R., Branco L., Galrinho A. et al. Cardiac myxoma: a13-year experience in echocardiographic diagnosis // Rev.Port. Cardiol.– 2010.– Vol. 29, N 7.– P. 1087–1100.
7. Shetty R., Radin M., Sarabi D., Shaoulian E. Familial recurrentatrial myxoma: Carney’s complex // Clin. Cardiol.– 2011.–Vol. 34, N 2.– P. 83–86.
8. Yavuz S., Eris C., Sezen M. et al. Recurrent multiple cardiacmyxomas // Bratisl. Lek. Listy.– 2010.– Vol. 111, N 10.–P. 549–551.

A case of surgical treatment coarctation of the aorta in adults

N.A. Ozerianskyi, I.O. Aksоnova, V.Yu. Vashkeba, V.V. Sakalov,V.G. Karpenko, O.M. Dovgan, B.M. Todurov

References

1. Банкл Т. Врожденные пороки сердца и крупных сосудов.– М.: Медицина,1980.– 189 с.
2. Зіньковський М.Ф. Врожденные пороки сердца / За ред.А.Ф. Возіанова.– К.: Книга плюс, 2008.– 1168 с.
3. Матчин Ю.Г., Козлов С.Г., Лякишев А.А. и др. Благоприят-ное течение коарктации аорты // Кардиология.– 1991.–Т. 31, № 12.– C. 105–106.
4. Becker A.E., Becker M.J., Edwards J.E. Anomalies associatedwith сoarctation of aorta-particular reference to infancy //Circulation.– 1970.– Vol. 41.– P. 1067–1075.
5. Bonnet L.M. Sur la lesion dite stenose congenitale de l’aortadans la region // Del isthme Revue de medicine.– 1903.–N 23.– P. 108, 225, 385.
6. Cobenoglu A., Teply F., Grunkemeier G. et al. Coarctation pf the aorta in patients younger than three months // A. Thorac. Cardiovasc. Surg.– 1985.– Vol. 89.– Р. 128–135.
7. Fyler D.C. Report of the New England Regional Infant Cardiac Program // Pediatrics.– 1980.– Vol. 65 (Suppl.).– P. 376–461.
8. Goldman S., Hernandez F., Pappas G. Results of surgical treatment of coarctation of the aorta in the critically ill neo- nate // A. Thorac. Cardiovasc. Surg.– 1986.– Vol. 91.– Р. 732–737.
9. Keith J.D. Coarctation of the aorta // Heart disease in infancy and childhood / Eds. J.D. Keith, R.D. Rowe, P. Vlad.– 3rd ed.– N.Y.: Macmillan, 1978.– P. 736–760.

Epidemiology, pathophysiology and risk factors of thromboembolic complications in atrial fibrillation

O.I. Dyadyk, L.S. Kholopov, O.V. Shchukina, N.O. Prokopenko, O.Y. Zaitseva, K.I. Chernyaeva

References

1. Бобров В.О., Жарінов О.Й., Ягенський А.В. та ін. Фібриляція передсердь: сучасна класифікація, принципи ведення хворих: методичні рекомендації. – К. 2001. –31 с.
2. Дзяк Г.В., Васильева Л.И., Сапожниченко Л.В. и др. Антикоагулянты непрямого действия в кардиологии: показания и противопоказания, дозирование и осложнения // Ліки України. – 2009. – №7. – С.115-121.
3. Дзяк Г.В., Жарінов О.Й. Фібриляція передсердь. – Київ: «Четверта хвиля», 2011. – 192 с.
4. Дядык А.И. Фибрилляция предсердий. – Донецк, КП «Регион». – 2001. – 390 с.
5. Жарінов О.Й. , Сороківський М.С. , Файник А.Ф. , Павлик С.С. Миготлива аритмія у хворих з гострим інфарктом міокарда: патогенез, клінічний перебіг, особливості лікування // Укр. кардіол. журн. – 2003. – № 2. – С.118-123.
6. Икоркин М.Р., Жаринов О.И. , Левчук Н.П. и др. Диагностические возможности чреспищеводной эхокардиографии у больных с фибрилляцией предсердий // Укр. кардіол. журн. – 2008. – № 3. – С. 102-110.
7. Исаева М.Ю., Зотова И.В., Алехин М.Н. и др. Выявление тромба ушка левого предсердия у больных с мерцательной аритмией и факторами риска тромбоэмболических осложнений: роль чреспищеводной эхокардиографии и мультиспиральной компьютерной томографии // Кардиология. – 2007. – № 3. – С. 58-62.
8. Кушаковский М. С. Аритмии сердца. – СПб.: ИКФ «Фолиант», 1998. – 640 с.
9. Кушаковский М.С. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика). – СПб.: ИКФ «Фолиант», 1999. – 176 с.
10. Пархоменко А.Н. Риск развития тромбоэмболических осложнений у больных с мерцательной аритмией и применение антикоагулянтов и антиагрегантов для профилактики инсульта / А.Н. Пархоменко // Укр. кардіол. журн. – 2002. – Додаток 2. – С. 4-14.
11. Принципи ведення хворих з фібриляцією та тріпотінням передсердь. Рекомендації Робочої групи з порушень серцевого ритму Українського наукового товариства кардіологів. – К., 2002. – 42 с.
12. Резолюція засідання групи експертів з інноваційних технологій у клінічній аритмології Асоціації кардіологів України (28 травня 2010 р., м. Київ) // Укр. кардіол. журн. – 2010. – № 3. – С. 128-129.
13. Рекомендації Асоціації кардіологів України з діагностики, лікування та профілактики хронічної серцевої недостатності у дорослих (2009). – К., 2009. – 22 с.
14. Сичов О.С. , Солов’ям Г.М., Срібна О.М. та ін. Європейське оглядове дослідження фібриляції передсердь: результати, отримані в Україні (клініко-демографічні показники) //Укр. кардіол. журн. – 2006. – № 1. – С. 30-34.
15. Сороківський М.С., Жарінов О.Й., Тумак І.М., Черняга-Ройко У.П. Поширеність та клінічний перебіг фібриляції передсердь у хворих з гострим інфарктом міокарда // Укр. кардіол. журн. – 2005. – № 2. – С.9-24.
16. Срібна О.М. Поширеність порушень ритму та провідності серед сільського населення України / Срібна О.М., Горбась І.М. // Укр. кардіол. журн. – 2008. – № 2. – С. 89-94.
17. Сычев О.С. Диагностика и лечение фибрилляции предсердий / Руководство по кардиологии / Под ред. В.Н.Коваленко. – К.: Морион, 2008. – С.1114-1140.
18. Чазова Е.И., Голицына С.П. Руководство по нарушениям ритма сердца / Под ред. Е.И. Чазова, С.П. Голицына. – М.: ГЭОТАР-Медиа, 2008. – 414 с.
19. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III (SPAF III) randomised clinical trial // Lancet. – 1996. – Vol.348. – P.633-638.
20. Anderson J.L., Halperin J.L., Albert N.M. et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS guideline recommendations): a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines // J. Amer. Coll. Cardiol. – 2013. – Vol.61. – P.1935–1944.
21. Azzam H.A.G. The thrombogenic role of platelets in valvular atrial fibrillation // Atrial fibrillation – basic research and clinical applications; ed. by J. Choi. – Croatia, 2011. – Сh.4. – P.63-80.
22. Azzam H.A.G. Thrombogenesis in atrial fibrillation // Atrial Fibrillation – Mechanisms and Treatment / Ed. by Tong Liu . – InTech, 2013. – ch.6. – P.127-151.
23. Bassand J.-P. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents // Europace. – 2012. – Vol.14. – P. 312–324.
24. Boyd A.C., McKay T., Nasibi S. et al. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation // Eur. Heart J. Cardiovasc. Imaging. – 2013. – Vol.14, № 3. – P.269-275.
25. Camm A.J., Kirchhof P. , Lip G.Y.H. et al. Guidelines for the management of atrial fibrillation // Eur. Heart J. – 2010. – Vol.31. – P.2369–2429.
26. Camm A.J., Lip G.Y.H., De Catherina R. et al. 2012 focused update of the ESC Guidelines for management of atrial fibrillation // Eur. Heart J. – 2012. – Vol.33. – P.2719-2747.
27. Caterina R., Husted S., Wallentin L. et al. Anticoagulants in heart disease: current status and perspectives // Eur. Heart J. – 2007. – Vol.28, No.7. –P. 880-913.
28. Cid-Conde L., López-Castro J. New Oral Anticoagulants in Atrial Fibrillation // Atrial Fibrillation – Mechanisms and Treatment / Ed. by Tong Liu . –InTech, 2013. – Ch.9. – P.207-227.
29. Cohen A., Ederhy S. , Meuleman C. et al. D-dimers in atrial fibrillation: a further step in risk stratification of thrombo-embolism? // Eur. Heart J. – 2007. – Vol.28, No.18. –P. 2179-2180.
30. Connolly S.J. , Laupacis A., Gent M. et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study // J. Am. Coll. Cardiol. – 1991. – Vol.18. – P.349-355.
31. Coppens M., Eikelboom J.W., Hart R.G. et al. The score identifies those patients with atrial fibrillation CHA2DS2-VASc and CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy // Eur. Heart J. – 2013. – Vol.34. – P.170-176.
32. Donal E., Ollivier R., Veillard D. et al. Left atrial function assessed by transthoracic echocardiography in patients treated by ablation for a lone paroxysmal atrial fibrillation // Eur. J. Echocardiography. – 2010. – Vol.11. – P.845-852.
33. Donal E., Sallach J.A., Murray R.D. et al. Contrast-enhanced tissue Doppler imaging of the left atrial appendage is a new quantitative measure of spontaneous echocardiographic contrast in atrial fibrillation // Eur. Heart J. – 2008. – Vol.9. – P.5-11.
34. Doukky R., Khandelwall A., Garcia-Sayan E. et al. External validation of a novel transthoracic echocardiographic tool in predicting left atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation // Eur. Heart J. Cardiovasc. Imaging. – 2013. – Vol.14, № 9. – P.876-881.
35. Erdoran O. Risk assessment and therapy decision in patients at low risk for stroke: CHA2DS2-VASc vs CHADS2 // Eur. Heart J. – 2013. – Vol.34. – P.168-169.
36. Ezekowitz M.D. , Bridgers S.L., James K.E. et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation / Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF) Investigators // N. Engl. J. Med. – 1992. – Vol.327. – P.1406-1412.
37. Ezekowitz M.D., Connolly S., Parekh A. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran // Amer. Heart J. – 2009. – Vol.157. – P.805-810.
38. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J. – 2010. – Vol.31. – P.967-975.
39. Fu R., Wu S., Wu P. et al. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation // Europace. – 2011. – Vol.13. – P.31-36.
40. Fuster V., Rydén L.E., Cannom D.S. et al. 2011 ACCF/AHA/HRS focused updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines // J. Am. Coll. Cardiol. – 2011. – Vol.57, №11. – P.e101-e198.
41. Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation // J. Amer. Med. Assoc. – 2001. – Vol.285. – P. 2864-2870.
42. Go A.S., Fang M.C., Udaltsova N. et al. Impact of Proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The anticoagulation and risk factors in atrial fibrillation (ATRIA) study // Circulation. – 2009. – Vol.119. – P.1363-1369.
43. Go A.S., Hylek E.M., Chang Y. et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? // J. Amer. Med. Assoc. – 2003. – Vol.290. – P.2685–2692.
44. Goldberg Y.H., Gordon S.C., Spevack D.M., Gordon G.M. Disparities in emptying velocity within the left atrial appendage // Eur. J. Echocardiogr. – 2010. – Vol.11, No.3. – P.290-295.
45. Granger C.B., Alexander J.H., McMurray J.J.V. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation // N. Engl. J. Med. – 2011. – Vol.365. – P. 981-992.
46. Guyatt G.H., Akl E.A., Crowther M. et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest. – 2012. – Vol.141, Suppl.2. – P.7S-47S.
47. Habara S., Dote K., Kato M. et al.Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation // Eur. Heart J. – 2007. – Vol.28. – P.2217-2222.
48. Hart R.G., Eikelboom J.W., Ingram A.J. et al. Anticoagulants in atrial fibrillation patients with chronic kidney disease // Nat. Rev. Nephrol. – 2012. – Vol.8. – P.569-578.
49. Healey J.S., Eikelboom J., Wallentin L. et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study // J. Amer. Coll. Cardiol. – 2010. – Vol.55, Suppl.10. – P.4-37.
50. Heeringa J., van der Kuip D.A., Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study / // Eur. Heart J. – 2006. – Vol.27. – P.949-953.
51. Hijazi Z., Oldgren J., Siegbahn A. et al. Novel therapeutic concepts: Biomarkers in atrial fibrillation: a clinical review // Eur. Heart J. – 2013. – Vol.34, No.20. –P. 1475-1480.
52. Holbrook A., Schulman S. , Witt D.M. et al. Evidence-Based Management of Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines // Chest. – 2012. – Vol.141, Suppl.2. – P.e152S–e184S
53. Hughes M., Lip G.Y.H. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk stratification schema and cost effectiveness data // Thrombosis and Haemostasis. – 2008. – Vol.99. – P.295-304.
54. Lane D.A., Lip G.Y.H. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation // Circulation. – 2012. – Vol.126. – P.860-865.
55. Lee M., Saver J.L., Chang K-H. et al. Low glomerular filtration rate and risk of stroke: meta-analysis // British Med. J. – 2010. – Vol.341. – P.42-49.
56. Leong D.P., Eikelboom J.W., Healey J.S. et al. Atrial fibrillation is associated with increased mortality: causation or association? // Eur. Heart J. – 2013. – Vol.34. – P.1027-1030.
57. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation // Chest. – 2010. – Vol.137. – P.263–272.
58. Lip G.Y.H., Tse H.F., Lane D.A. Atrial fibrillation // Lancet. – 2012. – Vol.379. – P.648-661.
59. Lowe B.S., Chung M.K., Klein A.L. Antithrombotic treatment and cardioversion of patients with atrial fibrillation // Atrial Fibrillation – From Bench to Bedside / Ed. by A. Natale and J. Jalife. – Totowa, NJ: Humana Press, 2008. – Ch.12. – 169-184.
60. Lubitz S.A., Rosen A.B., Ellinor P.T. et al. Stroke risk in AF: do AF patterns matter? // Eur. Heart J. – 2010. – Vol.31. – P.908-910.
61. Mahe I., Drouet L., Simoneau G. et al. D-dimer can predict survival in patients with chronic atrial fibrillation // Blood Coagul. Fibrinolysis. – 2004. – Vol.15. – P.413–417.
62. Manning W.J., Douglas P.L. Transesophageal echocardiography and atrial fibrillation: added value or expensive toy // Ann. Intern. Med. –1998. – Vol. 128. – P. 685-687.
63. Medi C., Hankey G.J., Freedman S.B. Stroke risk and antithrombotic strategies in atrial fibrillation. // Stroke. – 2010. – Vol.41, № 11. – P.2705-2713.
64. MiyasakaY., BarnesM.E., Gersh B.J. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence // Circulation. – 2006. – Vol.114, № 2. – P.119-125.
65. Montoro-Garcia S., Marin F., Lip G.Y.H. Thrombogenesis in lone atrial fibrillation: a role for soluble P-selectin? / // Europace. – 2011. – Vol.13. – P. 3-4.
66. Nieuwlaat R., Dinh T. , Olsson S.B. et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? // Eur. Heart J. – 2008. – Vol.29. – P.915–922.
67. Nozawa T., Inoue H., Hirai T. et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation // Int. J. Cardiol. – 2006. – Vol.109. – P.59–65.
68. Park J.H., Joung B., Son N.-H. et al. The electroanatomical remodelling of the left atrium is related to CHADS2/CHA2DS2VASc score and events of stroke in patients with atrial fibrillation // Europace. – 2011. – Vol.13. – P.1541-1549.
69. Petersen P. , Boysen G. , Godtfredsen J. et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study // Lancet. – 1989. – Vol.1. – P.175-179.
70. Pisters R., Lane D.A., Marin F. et al. Stroke and thromboembolism in atrial fibrillation // Circulation J. – 2012. – Vol.76. – P.2289-2304.
71. Providencia R., Trigo J., Paiva L. et al. The role of echocardiography in thromboembolic risk assessment of patient with non-valvular atrial fibrillation // J. Amer. Coll. Cardiol. – 2013. – Vol.26. – P.801-812.
72. Saksena S., Sra J., Jordaens L. et al. A prospective comparison of cardiac imaging using intracardiac echocardiography with transesophageal echocardiography in patients with atrial fibrillation. The intracardiac echocardiography guided cardioversion helps interventional procedures study // Circ. Arrhythm. Electrophysiol. – 2010. – Vol.3. – P.571-577.
73. Shah D. Atrial fibrillation burden: a ‘hard’ indicator of therapeutic efficacy and a prognostic marker to boot? // Eur. Heart J. – 2008. – Vol.29. – P.964–965.
74. Sohara H., Amitani S., Kurose M. et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation // J. Am. Coll. Cardiol. –1997. – Vol. 29. – P. 106-112.
75. Stoddard M.F. Risk of thromboembolism in new onset or transient atrial fibrillation // Progr. Cardiovasc. Dis. – 1996. – Vol.39. – P.69-80.
76. Stroke in AF working group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review // Neurology. – 2007. – Vol.69. – P.546–554.
77. Stroke Prevention in atrial fibrillation Study. Final results / SPAF Investigators // Circulation. – 1991. – Vol.84, No.2. – P.527-539.
78. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation / The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) Investigators // N.Engl.J.Med. – 1990. – Vol.323, No.22. – P.1505-1511.
79. Van Staa T.P., Setakis E., Di Tanna G.L. et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice // J. Thromb. Haemost. – 2011. – Vol.9. – P.39–48.
80. Velu S., Lip G.Y. Recent progress in antithrombotic therapy for atrial fibrillation // J. Atheroscler. Thromb. – 2011. – Vol.18, № 4. – P.257-273.
81. Waldo A.L. Anticoagulation: stroke prevention in patients with atrial fibrillation // Cardiol. Clin. – 2009. – Vol.27, № 1. – P.125-135.
82. Weijs B., de Vos C.B., Tieleman R.G. et al.The occurrence of cardiovascular disease during 5-year follow-up in patients with idiopathic atrial fibrillation // Europace. – 2013. – Vol.15, № 1. – P.18-23.
83. Wheeler R., Masani D. The role of echocardiography in the management of atrial fibrillation // Eur. J. Echocardiography. – 2011. – Vol.12. – P.133-138.
84 .You J.J., Singer D.E., Howard P.A. et al. Antithrombotic Therapy for Atrial Fibrillation Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest. – 2012. – Vol.141, Suppl.2. – P.e531S-e575S.

Almanac 2013: acute coronary syndromes

P. Meier , A.J. Lansky , A. Baumbach

References

1. Abe D., Sato A., Hoshi T. et al. Initial culprit-only versus initial multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: results from the Ibaraki Cardiovascular Assessment Study registry // Heart Vessels.– 2013.– March 26th (Epub ahead of print).
2. Adielsson A., Hollenberg J., Karlsson T. et al. Increase in survival and bystander CPR in out-of-hospital shockable arrhythmia: bystander CPR and female gender are predictors of improved outcome. Experiences from Sweden in an 18-year perspective // Heart.– 2011.– Vol. 97.– P. 1391–1396.
3. Alfonso F., Dutary J., Paulo M. et al. Combined use of optical coherence tomography and intravascular ultrasound ima- ging in patients undergoing coronary interventions for stent thrombosis // Heart.– 2012.– Vol. 98.– P. 1213–1220.
4. Arrich J., Holzer M., Havel C. et al. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation // Cochrane Database Syst. Rev.– 2012.– Vol. (9).– P. CD004128.
5. Baklanov D.V., Kaltenbach L.A., Marso S.P. et al. Theprevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011) // J. Am. Coll. Cardiol.– 2013.– Vol. 61.– P. 420–426.
6. Bhatt D.L., Stone G.W., Mahaffey K.W. et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events // New Engl. J. Med.– 2013.– Vol. 368.– P. 1303–1313.
7. Brener S.J., Milford-Beland S., Roe M.T. et al. Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report // Am. Heart J.– 2008.– Vol. 155.– P. 140–146.
8. Brooks S.C., Bigham B.L., Morrison L.J. Mechanical versus manual chest compressions for cardiac arrest // Cochrane Database Syst Rev.– 2011.– P. CD007260, doi.10.1002/ 14651858.CD007260.pub2.
9. Brown J.P., Clark A.M., Dalal H. et al. Patient education in the management of coronary heart disease // Cochrane Database Syst. Rev.– 2011.– P. CD008895.
10. Cafri C., Zahger D., Merkin M. et al. Efficacy of the radialapproach for the performance of primary PCI for STEMI // J. Invasive Cardiol.– 2013.– Vol. 25.– P. 150–153.
11. Casado Arroyo R., Polo-Tomas M., Roncales M.P. et al. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy // Heart.– 2012.– Vol. 98.– P. 718–723.
12. De Luca G., Schaffer A., Wirianta J. et al. Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI // Int. J. Cardiol.– 2013 (Epub ahead of print).
13. Doherty P., Lewin R. The RAMIT trial, a pragmatic RCT of cardiac rehabilitation versus usual care: what does it tell us? // Heart.– 2012.– Vol. 98.– P. 605–606.
14. Eagle K.A., Nallamothu B.K., Mehta R.H. et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go // Eur. Heart J.– 2008.– Vol. 29.– P. 609–617.
15. Feldman D.N., Swaminathan R.V., Kaltenbach L.A. et al. Adoption of radial access and comparison of outcomes to femoral access in percutaneous coronary intervention: an updated report from the National Cardiovascular Data Registry (2007–2012) // Circulation.– 2013.– Vol. 127.– P. 2295–2306.
16. Focks J.J., Brouwer M.A., van Oijen M.G. et al. Concomitantuse of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review // Heart.– 2013.– Vol. 99.– P. 520–527.
17. Fothergill R.T., Watson L.R, Chamberlain D. et al. Increases in survival from out-of-hospital cardiac arrest: a five year study// Resuscitation.– 2013.– Vol. 84.– P. 1089–1092.
18. Hamon M., Pristipino C., Di Mario C. et al. Consensusdocument on the radial approach in percutaneo cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology // EuroIntervention.–2013.– Vol. 8.– P. 1242–1251.
19. Heran B.S., Chen J.M., Ebrahim S. et al. Exercise-based cardiac rehabilitation for coronary heart disease // Cochrane Database Syst Rev 2011.– P. CD001800, doi.10.1002/ 14651858.CD001800.pub2.
20. Jolly S.S., Shenkman H., Brieger D. et al. Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events // Heart.– 2011.– Vol. 97.– P. 197–202.
21. Jones D.A., Rathod K.S., Howard J.P. et al. Safety and feasibility of hospital discharge 2 days following primary percutaneous intervention for ST-segment elevation myocardial infarction // Heart.– 2012.– Vol. 98.– P. 1722– 1727.
22. Khavandi A., Freeman P., Meier P. Discharge after primary angioplasty at 24 h: feasible and safe or a step too far? // Cardiology.– 2013.– Vol. 125.– P. 176–179.
23. Kimmelstiel C., Zhang P., Kapur N.K. et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention // Circ. Cardiovasc. Interv.– 2011.– Vol. 4.– P. 171–179.
24. Klutstein M.W., Westerhout C.M., Armstrong P.W. et al. Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy // Am. Heart J.– 2013.– Vol. 165.– P. 583–590.
25. Knight C.J., Timmis A.D. Almanac 2011: acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardio- logy // Heart.– 2011.– Vol. 97.– P. 1820–1827.
26. Kubo T., Imanishi T., Takarada S. et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy // J. Am. Coll. Cardiol.– 2007.– Vol. 50.– P. 933–939.
27. Kushner F.G., Hand M., Smith S.C.Jr. et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/ SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines // J. Am. Coll. Cardiol.– 2009.– Vol. 54.– P. 2205–2241.
28. Lindsay A.C., Viceconte N., Di Mario C. Optical coherence tomography: has its time come? // Heart.– 2011.– Vol. 97.– P. 1361–1362.
29. Lodi-Junqueira L., de Sousa M.R., da Paixao L.C. et al. Does intravascular ultrasound provide clinical benefits for percutaneous coronary intervention with bare-metal stentimplantation? A meta-analysis of randomized controlled trials // Syst. Rev.– 2012.– Vol. 1.– P. 42.
30. Maehara A., Mintz G.S., Weissman N.J. Advances in intravascular imaging // Circ. Cardiovasc. Interv.– 2009.– Vol. 2.– P. 482–490.
31. Mamas M.A., Ratib K., Routledge H. et al. Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials // Heart.– 2012.– Vol. 98.– P. 303–311.
32. Mehta S.R., Jolly S.S., Cairns J. et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation // J. Am. Coll. Cardiol.– 2012.– Vol. 60.– P. 2490–2499.
33. Meier P., Baker P., Jost D. et al. Chest compressions before defibrillation for out-of-hospital cardiac arrest: a meta- analysis of randomized controlled clinical trials // BMC Med.– 2010.– Vol. 8.– P. 52.
34. Meier P., Frohlich G.M., Lansky A.J. Bleeding complications in percutaneous coronary interventions // Cardiology.– 2013.– Vol. 125.– P. 213–216.
35. Meier P., Windecker S., Lansky A.J. Radial versus femoral access for primary percutaneous coronary intervention: is there a preferred route to the heart? Heart.– 2012.– Vol. 98.– P. 269–270.
36. Members W.G., Roger V.L., Go A.S. et al. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association // Circulation.– 2012.– Vol. 125.– P. 2–220.
37. Nolan J.P., Lyon R.M., Sasson C. et al. Advances in the hospital management of patients following an out of hospital cardiac arrest // Heart.– 2012.– Vol. 98.– P. 1201– 1206.
38. Noman A., Zaman A.G., Schechter C. et al. Early discharge after primary percutaneous coronary intervention for ST-elevation myocardial infarction // Eur. Heart J. Acute Cardiovasc. Care.– 2013.– February 14th (epub ahead of print).
39. Oemrawsingh R.M., Lenderink T., Akkerhuis K.M. et al. Multimarker risk model containing troponin-T, interleukin
10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment eleva- tion acute coronary syndrome // Heart.– 2011.– Vol. 97.– P. 1061–1066.
40. Park K.W., Park J.J., Lee S.P. et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial // Heart.– 2012.– Vol. 97.– P. 641–647.
41. Perkins G.D., Brace S.J., Smythe M. et al. Out-of-hospital cardiac arrest: recent advances in resuscitation and effects on outcome // Heart.– 2011.– Vol. 98.– P. 529–535.
42. Politi L., Sgura F., Rossi R. et al. A randomised trial of target- vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up // Heart.– 2010.– Vol. 96.– P. 662–667.
43. Ratib K., Mamas M.A., Routledge H.C. et al. Influence of access site choice on incidence of neurologic complications after percutaneous coronary intervention // Am. Heart J.– 2013.– Vol. 165.– P. 317–324.
44. Ratib K., Routledge H., Mamas M.A. et al. Trends in access site choice and PCI outcomes: insights from the UK national PCI dataset // Heart.– 2012.– Vol. 98.– P. 28–29.
45. Rauch B., Riemer T., Schwaab B. et al. Short-term comprehensive cardiac rehabilitation after AMI is associated with reduced 1-year mortality: results from the OMEGA study // Eur. J. Prev. Cardiol.– 2013 doi.– P. 10.1002/14651858. CD008895.pub2.
46. Rollando D., Puggioni E., Robotti S. et al. Symptom onset-to- balloon time and mortality in the first seven years after STEMI treated with primary percutaneous coronary intervention // Heart.– 2012.– Vol. 98.– P. 1738–1742.
47. Sambu N., Radhakrishnan A., Dent H. et al. Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry // Heart.– 2012.– Vol. 98.– P. 706–711.
48. Schmidt M., Jacobsen J.B., Lash T.L. et al. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study // BMJ.– 2012.– Vol. 344.– P. 356.
49. Secco G.G., Marinucci L., Uguccioni L. et al. Transradial versus transfemoral approach for primary percutaneous coronary interventions in elderly patients // J. Invasive Cardiol.– 2013.– Vol. 25.– P. 254–256.
50. Simms A.D., Reynolds S., Pieper K. et al. Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003–2009: National Institute for Cardiovascular Outcomes Research (NICOR) // Heart.– 2012.– Vol. 99.– P. 35–40.
51. Stone G.W., Maehara A., Lansky A.J. et al. A prospective natural-history study of coronary atherosclerosis // New Engl. J. Med.– 2011.– Vol. 364.– P. 226–235.
52. Stone G.W., Maehara A., Witzenbichler B. et al. Intracoro- nary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial // JAMA.– 2012.– Vol. 307.– P. 1817–1826.
53. Stone G.W., Witzenbichler B., Guagliumi G. et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS- AMI): final 3-year results from a multicentre, randomised controlled trial // Lancet2011.– Vol. 377.– P. 2193–2204.
54. Stub D., Smith K., Bray J.E. et al. Hospital characteristics are associated with patient outcomes following out-of-hospital cardiac arrest // Heart.– 2011.– Vol. 97.– P. 1489–1494.
55. Tamhane U., Meier P., Chetcuti S. et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials // EuroIntervention.– 2009.– Vol. 5.– P. 384–393.
56. Terkelsen C.J., Sorensen J.T., Maeng M. et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention // JAMA.–2010.– Vol. 304.– P. 763–771.
57. Verschuren J.J., Jukema J.W. Pharmacogenetics of antiplatelet therapy: ready for clinical application? // Heart.– 2011.– Vol. 97.– P. 1268–1276.
58. Vlaar P.J., Mahmoud K.D., Holmes D.R Jr. et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis // J. Am. Coll. Cardiol.– 2011.– Vol. 58.– P. 692–703.
59. West R.R., Henderson A.H. Cardiac rehabilitation and exercise training // Heart.– 2013.– Vol. 99.– P. 753–754.
60. West R.R., Jones D.A., Henderson A.H. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction // Heart.–2012.– Vol. 98.– P. 637–644.
61. Wijns W., Kolh P., Danchin N. et al. Guidelines on myocardial revascularization // Eur. Heart J.– 2010.– Vol. 31.– P. 2501–2555.
62. Wijns W., Kolh P., Danchin N. et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. Heart J.– 2010.– Vol. 31.– P. 2501–2555.
63. Wood D. Is cardiac rehabilitation fit for purpose in the NHS: maybe not // Heart.– 2012.– Vol. 98.– P. 607–608.
64. Yabushita H., Bouma B.E., Houser S.L. et al. Characterization of human atherosclerosis by optical coherence tomography// Circulation.– 2002.– Vol. 106.– P. 1640–1645.
65. Yeh RW., Sidney S., Chandra M. et al. Population trends in the incidence and outcomes of acute myocardial infarction //New Engl. J. Med.– 2010.– Vol. 362.– P. 2155–2165.

Angiographic Outcomes in the PLATO

V. Kunadian, S.K. James, D.M. Wojdyla, C. Zorkun, J. Wu, R.F. Storey,Ph.G. Steg, H. Katus, H. Emanuelsson, J. Horrow, J. Maya,L. Wallentin, R.A. Harrington, C.M. Gibson

References

1. Alexopoulos D., Xanthopoulou I., Gkizas V. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction // Circ. Cardiovasc. Interv.– 2012.– Vol. 5.– P. 797–804. 
2. Anderson S.D., Shah N.K., Yim J., Epstein B.J. Efficacy and safety of ticagrelor: A reversible P2Y12 receptor antagonist // Ann. Pharmacother.– 2010.– Vol. 44.– P. 524–537.
3. Berger J.S., Roe M.T., Gibson C.M. et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptorantagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid Reversal of Platelet Thrombosis With Intravenous Elinogrel Before PCI To Optimize Reperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial // Am. Heart J.– 2009.– Vol. 158.– P. 998–1004.
4. Gabriel H.M., Oliveira J.A., da Silva P. C. et al. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early Reopro Administration in Myocardial Infarction (ERAMI) trial // Catheter Cardiovasc. Interv.– 2006.– Vol. 68.– P. 218–224. 
5. Gibson C.M., Cannon C.P., Daley W.L. et al. TIMI frame count: a quantitative method of assessing coronary artery flow // Circulation.– 1996.– Vol. 93.– P. 879–888.
6. Gibson C.M., Cannon C.P., Murphy S.A. et al. Relationship of IMI myocardial perfusion grade to mortality after administration of thrombolytic drugs // Circulation.– 2000.– Vol. 101.– P. 125–130.
7. Gibson C.M., Cannon C.P., Murphy S.A. et al., for the TIMIStudy Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction // Circulation.– 2002.– Vol. 105.– P. 1909–1913.
8. Gibson C.M., Cohen D.J., Cohen E.A. et al. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy): Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy // Am. J. Cardiol.– 2001.– Vol. 87.– P. 1293–1295.
9. Gibson C.M., Morrow D.A., Murphy S.A. et al., for the TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial // J. Am. Coll. Cardiol.– 2006.– Vol. 47.– P. 2364–2373.
10. Gibson C.M., de Lemos J.A., Murphy S.A. et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy // Circulation.– 2001.– Vol. 103.– P. 2550–2554.
11. Gibson C.M., Murphy S.A., Morrow D.A. et al. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction // Am. Heart J.– 2004.– Vol. 148.– P. 336–340.
12. Gurbel P.A., Bliden K.P., Butler K. et al. Randomized doubleblindassessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study // Circulation.– 2009.– Vol. 120.– P. 2577–2585.
13. Gurbel P.A., Bliden K.P., Butler K. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study // Circulation.– 2010.– Vol. 121.– P. 1188–1899.
14. Husted S., Emanuelsson H., Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin // Eur. Heart J.– 2006.– Vol. 27.– P. 1038–1047.
15. Husted S.E., Storey R.F., Bliden K. et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies // Clin. Pharmacokinet.– 2012.– Vol. 51.– P. 397–409.
16. James S., Akerblom A., Cannon C.P. et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the Platelet Inhibition and Patient Outcomes (PLATO) trial // Am. Heart J.– 2009.– Vol. 157.– P. 599–605.
17. Kunadian V., Zorkun C., Williams S.P. et al. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction // J. Thromb. Thrombolysis.– 2008.– Vol. 26.– P. 234–242.
18. Petronio A.S., Rovai D., Musumeci G. et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty // Eur. Heart J.– 2003.– Vol. 24.– P. 67–76.
19. Schneider D.J. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists // Br. J. Clin. Pharmacol.– 2011.– Vol. 72.– P. 672– 682.
20. Schneider D.J. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy // J. Am. Coll. Cardiol.– 2011.– Vol. 57.– P. 685–687.
21. Stoel M.G., Marques K.M., de Cock C.C. et al. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study // Catheter. Cardiovasc. Interv.– 2008.– Vol. 71.– P. 283–289.
22. Storey R.F., Husted S., Harrington R.A. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes // J. Am. Coll. Cardiol.– 2007.– Vol. 50.– P. 1852–1856.
23. Teng R., Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects // Eur. J. Clin. Pharmacol. 2010.– Vol. 66.– P. 487–496.
24. TIMI Study Group. The Thrombolysis In Myocardial Infarction (TIMI) trial: phase I findings // New Engl. J. Med.– 1985.– Vol. 312.– P. 932–936.
25. Van Giezen J.J., Sidaway J., Glaves P. et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model // J. Cardiovasc. Pharmacol. Ther.– 2012.– Vol. 17.– P. 164–172.
26. Vijayalakshmi K., Kunadian B., Whittaker V.J. et al. Impact of catheter sizes and intracoronary glyceryl trinitrate on the TIMI frame count when digital angiograms are acquired at lower frame rates during elective angiography and PCI // Acute Card. Care.– 2007.– Vol. 9.– P. 231–238. 27. Vijayalakshmi K., Whittaker V.J., Kunadian B. et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes // Heart.– 2006.– Vol. 92.– P. 1278–1284. 28. Wallentin L., Becker R.C., Budaj A. et al., for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes // New Engl. J. Med.– 2009.– Vol. 361.– P. 1045–1057. 29. Wittfeldt A., Emanuelsson H., Brandrup-Wognsen G. et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans // J. Am. Coll. Cardiol.– 2013.– Vol. 61.– P. 723–727.